Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.
Neoplasia (New York, N.Y.) Feb, 2011 | Pubmed ID: 21403842